<DOC>
	<DOCNO>NCT00402415</DOCNO>
	<brief_summary>There two drug involve study . Sunitinib ( Sutent ( R ) ) approve Food Drug Administration ( FDA ) treatment advance renal cell ( kidney ) cancer gastrointestinal stromal tumor . Sunitinib think work block growth blood vessel tumor ; reduce blood supply tumor slow growth sometimes cause tumor shrink . Sirolimus approve FDA prevent body reject organ transplant . Sirolimus test effect cancer slow growth tumor animal model . Sirolimus think slow cancer growth animal model direct effect tumor cell , also block production growth factor stimulate production blood vessel . We hope combine use two drug well anti-cancer effect either agent alone . This study design find different dos Sirolimus combine standard dose Sutent safe well tolerate . Additionally , hop gain knowledge way Sutent ( R ) combination sirolimus affect blood vessel produce cancer .</brief_summary>
	<brief_title>Study Combination Sirolimus Sutent Patients With Advanced Solid Tumors Non-Curable With Standard Therapy</brief_title>
	<detailed_description />
	<mesh_term>Sunitinib</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>Patients must histologically confirm malignancy metastatic unresectable standard curative palliative measure exist longer effective . Patients previously untreated metastatic renal cell carcinoma eligible . Patients must measurable disease RECIST criterion . Patients must least 1 lesion locate neck , lung , solid organ ( include liver ) soft tissue abdomen pelvis , soft tissue low extremity 3 cm ideally &lt; 7 cm transaxial plane . Larger lesion may consider meet criterion . Index lesion must well demarcate . ECOG performance status 01 . Must ≥18 year age . Expected survival least 3 month . Women childbearing potential ( i.e. , woman premenopausal surgically sterile ) must use acceptable contraceptive method ( abstinence , intrauterine device [ IUD ] , oral contraceptive double barrier device ) , must negative serum urine pregnancy test within 1 week prior begin treatment trial . Nursing patient exclude . Sexually active men must also use acceptable contraceptive method . Pregnant nursing patient exclude effect combination SU11248 ( Sutent® ) sirolimus fetus nursing child unknown . Must able willing give write informed consent . Patients must follow clinical laboratory value : ANC count ≥1500/mm3 ; Platelets ≥100,000/mm3 ; Serum creatinine ≤2x upper limit normal . If serum creatinine upper limit normal ( less 2x normal ) , patient must measure 24 hour urine creatinine clearance ≥ 50 ml/min eligible ; Total bilirubin &lt; 1.5x upper limit normal ; Serum calcium &lt; 12.0 mg/dl ; Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) ≤3x upper limit normal ; Prothrombin Time ( PT ) , activate partial thromboplastin time ( aPTT ) INR normal range ; . Hemoglobin ≥9 gm/dl ( may correct transfusion ) . Normal cardiac ejection fraction Diagnosis history central nervous system ( CNS ) disease ( i.e . primary brain tumor , malignant seizure , CNS metastases carcinomatous meningitis ) . Any active uncontrolled bleeding patient bleed diathesis ( example , active peptic ulcer disease ) . Any grade 3 hemorrhage within 4 week prior start treatment . Any ongoing coagulopathies receive anticoagulant . Hypertension control medication ( &gt; 150/100 mm Hg despite optimal medical therapy ) . QTc interval &gt; 500 msec baseline EKG . Cardiac ejection fraction institutional low limit normal . Measured 24hour urine creatinine clearance &lt; 50 ml/min . Active infection kind . Unwilling unable follow protocol requirement give informed consent . Dyspnea rest minimal exertion . No treatment cytotoxic biologic agent within 4 week prior begin treatment study ( 6 week mitomycin nitrosoureas ) . At least 4 week must elapse prior surgery , radiation , hormonal drug therapy cancer . Patients must fully recover acute toxicity prior treatment cytotoxic drug , radiotherapy anticancer modality ( return baseline status note recent treatment ) . Patients persist , stable chronic toxicity prior treatment ≤ grade 1 eligible . Any follow within 6 month prior first dose treatment : myocardial infarction , symptomatic coronary artery disease ( severe unstable angina ) , artery bypass graft , uncontrolled arrhythmia , symptomatic congestive heart failure , cerebrovascular accident transient ischemic attack , pulmonary embolus . Known HIV infection . Patients HIV infection exclude may unknown dangerous drug interaction sirolimus/SU11248 ( Sutent® ) antiretroviral agent use treat HIV infection . Patients receive standard investigational treatment cancer , investigational agent indication . Diagnosis second malignancy ( except malignancy treat evidence recurrence least 5 year , curatively treat basal cell squamous cell carcinoma skin , situ cervical cancer , stage I malignancy &gt; 2 year treatment ) . Other severe acute chronic medical psychiatric condition laboratory abnormality may increase risk associate study participation study drug administration , may interfere interpretation study result , judgment investigator would make subject inappropriate entry study . Patients take concurrent medication kind strong inducer inhibitor CYP3A4 . Patients receive follow exclude : ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconazole , dexamethasone , phenytoin , carbamazepine , rifampin , rifabutin , rifapentin , phenobarbital , St. John 's Wort .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>metastatic</keyword>
	<keyword>malignancy</keyword>
	<keyword>advanced solid tumor</keyword>
	<keyword>unresectable</keyword>
	<keyword>Solid Tumors</keyword>
</DOC>